Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes✰-Reference-Cited by-同舟云学术

Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes✰

Published:2020-10 Issue: Volume:45 Page:102346
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Hunter Samuel F.^ORCID,Thomas Florian P.^ORCID,Cascione Mark,Williams Ian M.,Meng Xiangyi,Schofield Lesley,Weiss Jamie L.,Tenenbaum Nadia,Cree Bruce A.C.^ORCID

Funder

Novartis Pharmaceuticals Corporation

Biogen

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference32 articles.

1. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis;Agashivala;Clin. Ther.,2012

2. Improving adherence to injectable disease-modifying drugs in multiple sclerosis;Bayas;Expert Opin. Drug Deliv.,2013

3. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol.,2014

4. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis;Chard;Mult. Scler.,2004

5. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N. Engl. J. Med.,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting;Multiple Sclerosis and Related Disorders;2023-09